- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 June 2025 | 99 | GlobeNewswire (Europe) | Second quarter (April-June 2025)
Operating loss amounted to SEK -2,892,341 (-5,841,409).
Loss for the period amounted to SEK -2,732,070 (-5,622,779).
Cash flow from operating activities totaled... ► Artikel lesen | |
| 25.08. | ELICERA THERAPEUTICS: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 2 | Cision News | ||
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.08. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 87 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 25.08. | Elicera Therapeutics AB: Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee's Assessment in Cohort 2 | 94 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 28.05. | Elicera Therapeutics AB: Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201 | 138 | GlobeNewswire (Europe) | Gothenburg, May 28, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 22.05. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy | 137 | GlobeNewswire (Europe) | Gothenburg, May 22, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 15.05. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 31 March 2025 | 144 | GlobeNewswire (Europe) | First quarter (January-March 2025)
Operating loss amounted to SEK -8,069,404 (-5,433,422).
Loss for the period amounted to SEK -8,013,462 (-5,369,677).
Cash flow from operating activities totalled... ► Artikel lesen | |
| 14.04. | ELICERA THERAPEUTICS: Green light to continue Elicera's CARMA-trial in B-cell lymphoma | 2 | Cision News | ||
| 10.04. | Elicera Therapeutics AB: Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1 | 275 | GlobeNewswire (Europe) | Gothenburg, April 10, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2 | 3 | Cision News | ||
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 360 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 149 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen | |
| 28.11.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2024 | 108 | GlobeNewswire (Europe) | Third quarter (July-September 2024)
Operating profit/loss amounted to SEK -2,697,267 (-5,149,440).
Loss for the period amounted to SEK -2,514,629 (-5,046,574).
Cash flow from operating activities... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,876 | +0,51 % | Evotec: In der Gefahrenzone | "Noch lebt die Chance" lautet eine Formulierung, wie man sie aus dem Fußballsport kennt. Nach der Interpretation des Chartbildes der Evotec-Aktie bedeutet dies: Dieser Wert kann noch die Kurve kriegen... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 486,20 | +2,38 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 05.09.2025 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| BRAIN BIOTECH | 2,170 | 0,00 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech ernennt Johan Jansén-Storbacka zum Executive Vice President BRAINBiocatalysts für den Bereich Enzymprodukte | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Personalie
BRAIN Biotech ernennt Johan Jansén-Storbacka zum Executive Vice President BRAINBiocatalysts für den Bereich Enzymprodukte... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,945 | +2,83 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,440 | 0,00 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Sales of High-Purity Canola Protein | Vancouver, British Columbia--(Newsfile Corp. - September 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CSL | 116,38 | -3,16 % | Dividendenbekanntmachungen (09.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALUMINUM CORPORATION OF CHINA LTD CNE1000001T8 0,1348 HKD 0,0147 EUR AMEREN CORPORATION US0236081024 0,71 USD 0,6037 EUR ANHUI... ► Artikel lesen | |
| MANNKIND | 4,838 | +1,53 % | MannKind auf Morgan-Stanley-Konferenz: Strategische Diversifikation und Expansion in neue Therapiegebiete | ||
| OCULAR THERAPEUTIX | 11,335 | +1,57 % | Ocular Therapeutix auf der Baird-Konferenz: Strategische Fortschritte bei klinischen Studien | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,996 | +1,42 % | Oxford Nanopore price target raised to GBP2.10 from GBP1.90 at Deutsche Bank | ||
| ADAPTIMMUNE THERAPEUTICS | 0,045 | +2,30 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
| CODEXIS | 2,160 | +3,75 % | Benchmark reiterates Hold rating on Codexis stock after Q2 results | ||
| TELO GENOMICS | 0,049 | +4,30 % | Telo Genomics Corp.: Telo Geonomics Announces Engagement of Investor Relations Service Provider | Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that it has engaged Hayden IR, LLC.... ► Artikel lesen | |
| BIORA THERAPEUTICS | 0,001 | -100,00 % | NSE - BIORA THERAPEUTICS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CORMEDIX | 11,300 | +2,73 % | CorMedix, Inc.: CorMedix Announces Strategic Minority Investment in Talphera | BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for... ► Artikel lesen |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,036 (-6,05 %) liegt der Kurs bei 0,559 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.